Editas Medicine

$34.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$6.31 (-15.40%) Today

-$0.13 (-0.37%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell EDIT and other stocks, options, and ETFs commission-free!

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO

James C. Mullen

Employees

235

Headquarters

Cambridge, Massachusetts

Founded

2013

Market Cap

2.22B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.40M

High Today

$39.22

Low Today

$33.58

Open Price

$38.15

Volume

6.79M

52 Week High

$99.95

52 Week Low

$21.41

EDIT News

BenzingaApr 13

CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends

Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings a

Analyst Ratings

38%

of 13 ratings

Buy

38%

Hold

38%

Sell

23%

EDIT Earnings

-$1.00

-$0.63

-$0.25

$0.12

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 6, Pre-Market